Stay updated with breaking news from Natasha Drapeau. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Extended contract now covers a total of 11 European countries Crossject will receive milestone payments of up to €1 million in total, upon marketing authorizations Crossject will sell...
Dijon, France April 25, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceuticals company developing products for emergency...
Focusing on regulatory filings and accelerating U.S. commercialization efforts Contract of up to $155 million with BARDA for U.S. stockpiling continues to advance Dijon, France February 6, 2024...
Dijon, France, February 1, 2024 -- 18:15 CET - Crossject , a specialty pharma company developing needle-free auto-injectors for emergency situations, will hold a conference call on its commercial...
Dijon, France, February 1, 2024 -- 18:15 CET - Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free...